WBB Securities Reiterates “Buy” Rating for Omeros Corporation (OMER)

WBB Securities restated their buy rating on shares of Omeros Corporation (NASDAQ:OMER) in a research report report published on Thursday morning. They currently have a $75.00 target price on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on OMER. Maxim Group set a $19.00 price target on shares of Omeros Corporation and gave the company a buy rating in a research report on Wednesday, November 2nd. FBR & Co reiterated an outperform rating and set a $38.00 price target on shares of Omeros Corporation in a research report on Tuesday, October 18th. Zacks Investment Research upgraded shares of Omeros Corporation from a sell rating to a hold rating in a research report on Wednesday, October 19th. Cantor Fitzgerald reiterated a buy rating and set a $21.00 price target on shares of Omeros Corporation in a research report on Friday, November 11th. Finally, Wedbush reiterated an outperform rating and set a $56.00 price target on shares of Omeros Corporation in a research report on Friday, October 21st. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Omeros Corporation has an average rating of Buy and a consensus target price of $33.23.

Analyst Recommendations for Omeros Corporation (NASDAQ:OMER)

Shares of Omeros Corporation (NASDAQ:OMER) opened at 12.27 on Thursday. The stock has a 50 day moving average of $9.72 and a 200-day moving average of $10.84. The company’s market capitalization is $526.57 million. Omeros Corporation has a 12-month low of $7.20 and a 12-month high of $16.80.

Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.06. The firm had revenue of $11.30 million for the quarter, compared to analyst estimates of $11.64 million. During the same quarter in the previous year, the business posted ($0.53) earnings per share. Omeros Corporation’s revenue for the quarter was up 253.1% on a year-over-year basis. Equities research analysts forecast that Omeros Corporation will post ($1.69) EPS for the current year.

In other news, VP Marcia S. Kelbon sold 16,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $10.91, for a total value of $174,560.00. Following the completion of the transaction, the vice president now owns 179,597 shares of the company’s stock, valued at $1,959,403.27. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 13.60% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Investment Management LLC raised its position in Omeros Corporation by 12.6% in the second quarter. BlackRock Investment Management LLC now owns 154,233 shares of the biopharmaceutical company’s stock valued at $1,623,000 after buying an additional 17,226 shares during the last quarter. BlackRock Advisors LLC raised its position in Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 173 shares during the last quarter. Vanguard Group Inc. raised its position in Omeros Corporation by 2.3% in the second quarter. Vanguard Group Inc. now owns 1,430,125 shares of the biopharmaceutical company’s stock valued at $15,045,000 after buying an additional 32,401 shares during the last quarter. Brown Advisory Inc. raised its position in Omeros Corporation by 4.0% in the second quarter. Brown Advisory Inc. now owns 543,763 shares of the biopharmaceutical company’s stock valued at $5,721,000 after buying an additional 21,133 shares during the last quarter. Finally, Nationwide Fund Advisors raised its position in Omeros Corporation by 0.9% in the second quarter. Nationwide Fund Advisors now owns 67,255 shares of the biopharmaceutical company’s stock valued at $708,000 after buying an additional 631 shares during the last quarter. 52.08% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “WBB Securities Reiterates “Buy” Rating for Omeros Corporation (OMER)” was first posted by Mideast Time and is owned by of Mideast Time. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at http://www.mideasttime.com/wbb-securities-reiterates-buy-rating-for-omeros-corporation-omer/1417263.html. <span

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2016 Mideast Time.